Juva Life Expands WIRB-Approved Cannabis Patient Registry Study

Company launches first U.S wide cannabis registry for Critical Research on How Cannabis Can Improve Public Health

REDWOOD CITY, Calif., Dec. 14, 2021 (GLOBE NEWSWIRE) -- Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRANKFURT: 4VV) (“Juva Life,” “Juva” or the “Company”), a life sciences portfolio company with operations in cannabis production and distribution as well as pharmaceutical research and development, announced today that the Company is currently seeking qualified participants for their WCG IRB (Puyallup, WA) -approved cannabis patient registry. The JuLi Registry, which is listed on clinicaltrials.gov, seeks to amass one of the world’s largest data sets of real world clinical evidence on the potential health benefits of cannabis , which will be used in clinical research programs in the future.

As a recognized leader at the forefront of unlocking the therapeutic value of cannabis, Juva Life created the registry to help researchers and clinicians understand how cannabis may provide symptomatic relief for certain conditions and improve health outcomes  for individuals. The study is open to patients over 21 years of age who have the following conditions or symptoms: chronic pain, anxiety, neuropathy, appetite issues, nausea, sleep issues, and menopausal symptoms. The goal of the registry is to collect data on cannabis formulations, chemical composition, dosing and utilization and the effectiveness of cannabis products in addressing these medical concerns. Additionally, the study will examine patients’ use of cannabis in conjunction with other prescription medication, including any discontinuation of the use of opioids or reduction in the use of opioids after initiation of cannabis-based medications.

At the conclusion of this multi-year study, Juva will have one of the largest data sets of its kind and be able to leverage the data in both its nutraceutical wellness, drug development and clinical programs. This  real world observational data, will be presented to various regulatory bodies as further proof-of-concept and proof-of-safety of the potential therapeutic benefits of cannabis and cannabis-derived compounds.

The study is open to patients who live in California and wish to use products that contain tetrahydrocannabinol (THC) and patients nationwide who will use cannabidiol (CBD) products not containing more than 0.3% THC. Interested participants will be required to complete periodic confidential surveys about their symptoms, medication use and results and are also encouraged to download a simple journaling app to document daily the cannabis products they consumed, what effect they had on their specific symptoms and side effects should they occur.

The Juva Life cannabis patient registry is led by a team of leading doctors and clinicians. It is fully compliant with best medical practices for clinical research. Those adults interested in participating should contact Juva Life at juvaresearch.com to check their eligibility and learn more about the study.

“The data our research team intends to gather as part of this study is extremely valuable,” said Peter Beitsch, MD, a renowned oncologist, medical researcher and Principal investigator of Juva Life’s Clinical Registry. “I’m involved because I have direct experience with patients who have been helped by cannabinoids. Of particular interest to me is the potential of cannabis as an alternative to opioid-based chronic pain relief, as well as ameliorating menopausal symptoms. This study will help further our understanding of the benefits of cannabinoids through real-world data gathering, thus enabling us to speak to the potential of cannabis in treating many chronic conditions.”

With its own cultivation, manufacturing, research, and retail operations, Juva Life is focused on ensuring quality control and efficient formulations throughout all stages of the cannabis supply chain. THC-containing products for the study will be provided through one of Juva’s licensed delivery services headquartered in Redwood City, CA. For patients interested in using CBD products, Juva has partnered with leading wellness brands such as San Benito Hemp Co in order to offer 50% discounted CBD products to patients nationwide.

“We’re excited to be launching this study here in Redwood City and across the nation now with our CBD partners,” said Doug Chloupek, CEO and Founder of Juva. “It makes sense that this kind of groundbreaking research would be happening here in California, the world’s largest legalized cannabis market. But, more importantly for us, this has the potential to inform healthier treatment options and better our communities through a more robust understanding about the power of cannabis and its medicinal qualities.”

ON BEHALF OF THE BOARD,

-Doug Chloupek-

Doug Chloupek, CEO and Founder

Juva Life Inc.

inquiries@juvalife.com

About Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRA: 4VV)

Juva Life is employing state-of-the-art science to discover, develop and commercialize safe and effective wellness and pharmaceutical products, in both the cannabis consumer segment as well as the non-cannabinoid based medical industry. The Company is successfully executing against its 2018 roadmap, initially starting with standardization of cultivation, extraction, and formulation to offer consumers reproducible benefits. Juva is building upon these natural product process chemistry skills, to now include discovery pharmacology. The Company will leverage revenue derived from its retail operations to advance its consumer and clinical development efforts of Juva-019 and Juva-041, as well as other potentially valuable non-cannabinoid bioactives with significant consumer and pharma products applications. Juva is working to bring the Cannabis market face to face with the sector’s next generation investment grade business model. Find out more at: https://juvalife.com/.

 

For further information, please contact:

Juva Life Investor Relations

Tel: +1 833-333-5882 (JUVA)

Email: inquiries@juvalife.com

Forward Looking Statement

This news release contains statements and information that, to the extent that they are not historical fact, may constitute “forward-looking information” within the meaning of applicable securities legislation. Forward-looking information may include financial and other projections, as well as statements regarding future plans, objectives, or economic performance, or the assumption underlying any of the foregoing. In some cases, forward-looking statements can be identified by terms such as “may”, “would”, “could”, “will”, “likely”, “except”, “anticipate”, “believe”, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook”, or the negative thereof or other similar expressions concerning matters that are not historical facts. Examples of such statements include, but are not limited to, statements with respect to the objectives and business plans of the Company; product development, commercialization strategy and future collaborations.

Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the forward-looking information, including, without limitation, risks relating to the future business plans of the Company; risks that the Company will not be able to retain its key personnel; risks that the Company will not be able to secure financing on reasonable terms or at all, as well as all of the other risks as described in the Company’s management discussion and analysis for year ended December 31, 2020 under the heading “Risks and Uncertainties”. Accordingly, readers should not place undue reliance on any such forward-looking information. Further, any forward-looking information speaks only as of the date on which such statement is made. New factors emerge from time to time, and it is not possible for the Company’s management to predict all of such factors and to assess in advance the impact of each such factor on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking information. The Company does not undertake any obligation to update any forward-looking information to reflect information or events after the date on which it is made or to reflect the occurrence of unanticipated events, except as required by law, including securities laws.

The CSE does not accept responsibility for the adequacy or accuracy of this release.

by Kyle Porter

Juva Life Reports 322% Increase in Revenue in 2021 Third Quarter Financial and Operational Results Filing

Juva Life Reports 322% Increase in Revenue in 2021 Third Quarter Financial and Operational Results Filing

Cannabis and Life Sciences Company Reports Q3 Results and Provides Comment on Operations

VANCOUVER, British Columbia, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRANKFURT: 4VV) (“Juva Life,” “Juva” or the “Company”), a life sciences portfolio company with operations in cannabis production and distribution as well as pharmaceutical research and development, today reported its financial and operating results for the three-month and nine-month periods ending September 30, 2021.

Q3 2021 Financial Summary

  • Revenue for Q3 2021 increased 322% when compared to the same period in 2020; from $.2 million to $1.2 million. This increase was driven by growth in its delivery business as well as sales from its initial cannabis harvests
  • Revenue for the nine months ended September 30, 2021 was $2.5 million vs $ .5 million for the same period in the previous year, a 390% increase
  • Gross profit for the quarter increased to $.51 million or 43.1% of revenue, compared to $.13 million in the same period in 2020
  • Total net expenses including non-cash items decreased from $3.1 million to $2.5 million for the quarter despite revenue increasing substantially
  • On September 30, 2021, working capital was $4.5 million

 

Q3 2021 Operational Highlights

  • Company focused on expansion of pharmaceutical research initiatives, through its Juva Research division
  • Company identified and nominated JUVA-019 for further clinical research and profile development, driven by top line results from an internal study that showed the non-cannabinoid compound has significant anti-inflammatory properties
  • Its Juva Stockton subsidiary received a state license for distribution for its Stockton, CA, facility, with the intention of a manufacturing license to follow
  • Started final phase of construction on its Stockton cultivation facilities, expected to be completed in the first quarter of 2022, and which will effectively triple the revenue generating capacity of the facility

“The third quarter of 2021 was without a doubt one of the most prosperous and pivotal quarters to date for our organization,” said Doug Chloupek, CEO and Founder of Juva. “Our legacy cannabis operations, which have been years in the making, really began to take off. We saw a massive increase in revenue from our delivery business, which continues to see growth in its customer base and product offering. Construction continued on our cultivation hub in Stockton, which I am happy to report is on track for completion in the beginning of next year. This expansion will more than triple our capacity with a minimal increase to our expenses. All in all, Q3 marked the first fully operating quarter of our vertically integrated cannabis business in California, the largest legalized cannabis market in the world, and we are just getting started. I am so proud of how the team executed and the fruits of those labors are becoming very apparent. Headed into the new year, we plan to further optimize our cannabis operations, focus on profitability and sustainable growth, and building upon the success we experienced this year.”

Chloupek added: “Beyond our cannabis operations, the third quarter may have been even more important for the scientific breakthroughs we experienced in our research division. From our inception, the core of Juva’s mission was to unlock the medical aspects of the cannabis plant through science and research. In August of this year, we announced top line results from pre-clinical research we conducted in-house, which resulted in our nomination of the first compound in our clinical development pipeline, JUVA-019. While found in the cannabis plant, the compound is not a cannabinoid, and we were able to successfully file a patent on its anti-inflammatory mode of action, giving Juva a truly unique value proposition in the cannabis research space. Since its identification and nomination, we have been conducting further research, including comparative and in vivo studies, which have shown that JUVA-019 has substantial anti-inflammatory properties, surpassing those of more commonly known cannabinoids such as CBD and THC. We are so excited by the discovery and truly believe we have found something naturally occurring in the cannabis plant that has the power to address one of the largest therapeutics markets in the world. We plan to further investigate this hypothesis in an expedited fashion in the coming month – and in a way that we believe creates a completely new value proposition for Juva as a company. Overall, I could not be more excited for where we are as an organization and the opportunity we have before us.”

ON BEHALF OF THE BOARD,

-Doug Chloupek-

Doug Chloupek, CEO and Founder

Juva Life Inc.

inquiries@juvalife.com

About Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRA: 4VV)

Juva Life is employing state-of-the-art science to discover, develop and commercialize safe and effective wellness and pharmaceutical products, in both the cannabis consumer segment as well as the non-cannabinoid based medical industry. The Company is successfully executing against its 2018 roadmap, initially starting with standardization of cultivation, extraction, and formulation to offer consumers reproducible benefits. Juva is building upon these natural product process chemistry skills, to now include discovery pharmacology. The Company will leverage revenue derived from its retail operations to advance its consumer and clinical development efforts of Juva-019 and Juva-041, as well as other potentially valuable non-cannabinoid bioactives with significant consumer and pharma products applications. Juva is working to bring the Cannabis market face to face with the sector’s next generation investment grade business model. Find out more at: https://juvalife.com/.

 

 

For further information, please contact:

Juva Life Investor Relations

Tel: +1 833-333-5882 (JUVA)

Email: inquiries@juvalife.com

Forward Looking Statement

This news release contains statements and information that, to the extent that they are not historical fact, may constitute “forward-looking information” within the meaning of applicable securities legislation. Forward-looking information may include financial and other projections, as well as statements regarding future plans, objectives, or economic performance, or the assumption underlying any of the foregoing. In some cases, forward-looking statements can be identified by terms such as “may”, “would”, “could”, “will”, “likely”, “except”, “anticipate”, “believe”, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook”, or the negative thereof or other similar expressions concerning matters that are not historical facts. Examples of such statements include, but are not limited to, statements with respect to the objectives and business plans of the Company; product development, commercialization strategy and future collaborations.

Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the forward-looking information, including, without limitation, risks relating to the future business plans of the Company; risks that the Company will not be able to retain its key personnel; risks that the Company will not be able to secure financing on reasonable terms or at all, as well as all of the other risks as described in the Company’s management discussion and analysis for year ended December 31, 2020 under the heading “Risks and Uncertainties”. Accordingly, readers should not place undue reliance on any such forward-looking information. Further, any forward-looking information speaks only as of the date on which such statement is made. New factors emerge from time to time, and it is not possible for the Company’s management to predict all of such factors and to assess in advance the impact of each such factor on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking information. The Company does not undertake any obligation to update any forward-looking information to reflect information or events after the date on which it is made or to reflect the occurrence of unanticipated events, except as required by law, including securities laws.

The CSE does not accept responsibility for the adequacy or accuracy of this release.

 

 

by Kyle Porter

Juva Life Launches Preclinical Comparative Study to Evaluate Anti-Inflammatory Properties of Candidate JUVA-019 in Conjunction With Other Well-Known Cannabinoids

Juva Life Launches Preclinical Comparative Study to Evaluate Anti-Inflammatory Properties of Candidate JUVA-019 in Conjunction With Other Well-Known Cannabinoids

Cannabis and Life Sciences Company Initiates Internal Study Comparing Anti-Inflammatory Properties of Candidate JUVA-019 When Combined With Cannabinoids Such as THC and CBD

VANCOUVER, British Columbia, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRANKFURT: 4VV) (“Juva Life,” “Juva” or the “Company”), a life sciences portfolio company with operations in cannabis production and distribution as well as pharmaceutical research and development, announced today that it has launched a pre-clinical comparative study on its proprietary molecular candidate JUVA-019, comparing its anti-inflammatory properties as a standalone compound and in combination with well-known cannabinoids such as tetrahydrocannabinol (THC) and cannabidiol (CBD). The goal of the study is to determine if Juva will advance JUVA-019 as a standalone compound, or if it will combine with other cannabinoids as a drug candidate with anti-inflammatory properties.

The study will be conducted in-house via Juva’s research team, led by Dr. Sanjeev Gangwar, Ph.D., who has an extensive background in pharmaceutical research and development. The study will follow a similar protocol used previously to identify JUVA-019. JUVA-019 will be evaluated in combination with multiple well-known cannabinoids, one at a time, and then all together to evaluate their inhibition of IL1-beta and TNF-alpha, which are some of the biomarkers in the body that indicate inflammation. The results will then be compared to the results from JUVA-019, identifying which combination or standalone compound is more effective at inhibition of multiple cytokines implicated in inflammation.

“This is an important step in the research protocol of our pharmaceutical program on JUVA-019,” said Doug Chloupek, CEO and Founder of Juva. “It’s widely believed that in order for cannabis to be effective as an anti-inflammatory, all of the cannabinoids found in the plant must be present, creating what is known as the Entourage Effect. While there is plenty of anecdotal evidence that cannabis holds anti-inflammatory properties, the true cause of the mode of action remains unknown. Our mission is to research this very question and identify compounds within the plant that cause a positive reaction in reducing inflammation in the body.”

Through the Company’s research division, Juva has already identified two proprietary compounds they believe may hold this potential: JUVA-019 and JUVA-041. Inflammation is a response in the body to signal potential danger or damage to organs. Inflammation can be either short-lived (acute) or long-lasting (chronic), with underlying triggers such as cancer, heart disease, asthma, and arthritis. According to recent estimates by Rand Corporation, in 2014 nearly 60% of Americans had at least one chronic condition, 42% had more than one and 12% of adults had 5 or more chronic conditions causing inflammation -- and worldwide, 3 of 5 people die due to chronic inflammatory diseases. The global anti-inflammatory therapeutics market is estimated to reach USD $191.4 billion by 2027, as reported by Fortune Business Insights.

Where many companies are conducting researching on well-known cannabinoids such as CBD and THC, Juva has identified two proprietary, non-cannabinoid compounds, JUVA-019 and JUVA-041, with potentially greater anti-inflammatory properties than cannabinoids. The goal of the announced study will be to combine JUVA-019 with popular cannabinoids such as CBD and THC and to evaluate the anti-inflammatory properties when combined versus as a standalone compound.

ON BEHALF OF THE BOARD,

-Doug Chloupek-

Doug Chloupek, CEO and Founder

Juva Life Inc.

inquiries@juvalife.com

About Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRA: 4VV)

Juva Life is employing state-of-the-art science to discover, develop and commercialize safe and effective wellness and pharmaceutical products, in both the cannabis consumer segment as well as the non-cannabinoid based medical industry. The Company is successfully executing against its 2018 roadmap, initially starting with standardization of cultivation, extraction, and formulation to offer consumers reproducible benefits. Juva is building upon these natural product process chemistry skills, to now include discovery pharmacology. The Company will leverage revenue derived from its retail operations to advance its consumer and clinical development efforts of Juva-019 and Juva-041, as well as other potentially valuable non-cannabinoid bioactives with significant consumer and pharma products applications. Juva is working to bring the Cannabis market face to face with the sector’s next generation investment grade business model. Find out more at: https://juvalife.com/.

For further information, please contact:

Juva Life Investor Relations

Tel: +1 833-333-5882 (JUVA)

Email: inquiries@juvalife.com

Forward Looking Statement

This news release contains statements and information that, to the extent that they are not historical fact, may constitute “forward-looking information” within the meaning of applicable securities legislation. Forward-looking information may include financial and other projections, as well as statements regarding future plans, objectives, or economic performance, or the assumption underlying any of the foregoing. In some cases, forward-looking statements can be identified by terms such as “may”, “would”, “could”, “will”, “likely”, “except”, “anticipate”, “believe”, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook”, or the negative thereof or other similar expressions concerning matters that are not historical facts. Examples of such statements include, but are not limited to, statements with respect to the objectives and business plans of the Company; product development, commercialization strategy and future collaborations.

Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the forward-looking information, including, without limitation, risks relating to the future business plans of the Company; risks that the Company will not be able to retain its key personnel; risks that the Company will not be able to secure financing on reasonable terms or at all, as well as all of the other risks as described in the Company’s management discussion and analysis for year ended December 31, 2020 under the heading “Risks and Uncertainties”. Accordingly, readers should not place undue reliance on any such forward-looking information. Further, any forward-looking information speaks only as of the date on which such statement is made. New factors emerge from time to time, and it is not possible for the Company’s management to predict all of such factors and to assess in advance the impact of each such factor on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking information. The Company does not undertake any obligation to update any forward-looking information to reflect information or events after the date on which it is made or to reflect the occurrence of unanticipated events, except as required by law, including securities laws.

The CSE does not accept responsibility for the adequacy or accuracy of this release.

by Kyle Porter

Juva Life Identifies Second Molecular Compound Found in Cannabis With Significant Anti-Inflammatory Therapeutic Properties Coined JUVA-041

Juva Life Identifies Second Molecular Compound Found in Cannabis With Significant Anti-Inflammatory Therapeutic Properties Coined JUVA-041

Cannabis and Life Sciences Company Adds Second Novel Non-Cannabinoid Compound to Pharmaceutical Pipeline

VANCOUVER, British Columbia, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRANKFURT: 4VV) (“Juva Life,” “Juva” or the “Company”), a life sciences portfolio company with operations in cannabis production and distribution as well as pharmaceutical research and development, announced today that it has identified a proprietary compound, JUVA-041, found in the cannabis sativa family of plants with significant anti-inflammatory properties.

Through its research division, Juva research scientists are evaluating an internally curated database of compounds found in the cannabis plant for their therapeutic benefit. The news follows the Company’s identification of non-cannabinoid compound JUVA-019, which the Company has filed a patent upon and also begun further preclinical research. In recent months, Juva has been developing a chemical library of natural and semi-synthetic non-cannabinoids found in the cannabis plant with the intention of identifying compounds with anti-inflammatory properties, with the first compound being identified as JUVA-019. Juva’s hypothesis is that the therapeutic potential of cannabis is widely known, yet the cause of the overarching medical benefits of cannabis is mostly undefined. While many speculate that cannabinoids such as tetrahydrocannabinol (THC) and cannabidiol (CBD) interacting with the endocannabinoid system are the cause of the benefit, Juva is taking a chemical approach to the research, looking further into the compounds present in the plant beyond cannabinoids that may have the benefit. As such, the Juva research team has built an extensive database of less studied compounds that it continues to evaluate for their anti-inflammatory potential, now having two compounds in its clinical pipeline: JUVA-019 and JUVA-041.

“Juva is a unique company in that we are leveraging our cannabis expertise to vertically integrate value-building science,” said Doug Chloupek, CEO and Founder of Juva. “While we remain focused on completing the build out and monetization of our cannabis cultivation and distribution facilities, this year we have expanded the scope in which Juva operates to now include translational research and development. Our team of scientists have taken a modern learning strategy to understand how cannabis works. While the current industry focus centers on cannabinoids, our strategy breaks from this school of thought and is focused on unappreciated non-cannabinoids with significant therapeutic potential. We have now identified two non-cannabinoid compounds that may begin to explain the clinical benefits of cannabis through an anti-inflammatory mode of action. We are excited to add to our commercial efforts in cannabis a proprietary R/D platform to execute our 2018 “farm to pharma” roadmap. Through these discoveries, and the ensuing work to follow, I can proudly state that Juva is no longer simply a cannabis operator, but a full-fledged life sciences company with existing plant-touching assets paired with industry-leading scientific research.”

JUVA-019 and JUVA-041 are now designated as lead compounds. The Company plans to conduct comparative studies on the candidates to determine if combining them with other cannabinoid or non-cannabinoid compounds increases the efficacy of the anti-inflammatory mode of action. Based on those results, Juva will either move forward with the standalone compounds, or the newly discovered, more effective formulations. After said results, the candidates will be developed in a 2-prong approach. The natural chemophores will be advanced unmodified and evaluated for select applications in the consumer nutraceutical and wellness categories. In parallel, standard medicinal chemistry tools will be applied to improve upon potency and absorption, distribution, metabolism, and excretion (ADME) properties. The compounds will be advanced through a standard pharma development stage/gate plan, beginning with profiling in industry-standard in vitro and in vivo models of inflammatory disease. This profile is necessary to attract the attention of larger pharmaceutical players who may be interested in the candidates for their own pipelines. The Company anticipates initiating non-clinical development within the next 6-9 months. This combined consumer and medical strategy reduces development cost, risk, and time, and creates an opportunity for Juva to unlock shareholder value sooner than other pharmaceutical competitors.

ON BEHALF OF THE BOARD,
-Doug Chloupek-
Doug Chloupek, CEO and Founder
Juva Life Inc.
inquiries@juvalife.com

About Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRA: 4VV)
Juva Life is employing state-of-the-art science to discover, develop and commercialize safe and effective wellness and pharmaceutical products, in both the cannabis consumer segment as well as the non-cannabinoid based medical industry. The Company is successfully executing against its 2018 roadmap, initially starting with standardization of cultivation, extraction, and formulation to offer consumers reproducible benefits. Juva is building upon these natural product process chemistry skills, to now include discovery pharmacology. The Company will leverage revenue derived from its retail operations to advance its consumer and clinical development efforts of Juva-019 and Juva-041, as well as other potentially valuable non-cannabinoid bioactives with significant consumer and pharma products applications. Juva is working to bring the Cannabis market face to face with the sector’s next generation investment grade business model. Find out more at: https://juvalife.com/.

For further information, please contact:
Juva Life Investor Relations
Tel: +1 833-333-5882 (JUVA)
Email: inquiries@juvalife.com

Forward Looking Statement
This news release contains statements and information that, to the extent that they are not historical fact, may constitute “forward-looking information” within the meaning of applicable securities legislation. Forward-looking information may include financial and other projections, as well as statements regarding future plans, objectives, or economic performance, or the assumption underlying any of the foregoing. In some cases, forward-looking statements can be identified by terms such as “may”, “would”, “could”, “will”, “likely”, “except”, “anticipate”, “believe”, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook”, or the negative thereof or other similar expressions concerning matters that are not historical facts. Examples of such statements include, but are not limited to, statements with respect to the objectives and business plans of the Company; product development, commercialization strategy and future collaborations.

Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the forward-looking information, including, without limitation, risks relating to the future business plans of the Company; risks that the Company will not be able to retain its key personnel; risks that the Company will not be able to secure financing on reasonable terms or at all, as well as all of the other risks as described in the Company’s management discussion and analysis for year ended December 31, 2020 under the heading “Risks and Uncertainties”. Accordingly, readers should not place undue reliance on any such forward-looking information. Further, any forward-looking information speaks only as of the date on which such statement is made. New factors emerge from time to time, and it is not possible for the Company’s management to predict all of such factors and to assess in advance the impact of each such factor on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking information. The Company does not undertake any obligation to update any forward-looking information to reflect information or events after the date on which it is made or to reflect the occurrence of unanticipated events, except as required by law, including securities laws.

The CSE does not accept responsibility for the adequacy or accuracy of this release.

by Kyle Porter

Juva Life Files Patent on Family of Non-Cannabinoid Small Molecules Targeting Consumer and Pharma Inflammatory Indications

Juva Life Files Patent on Family of Non-Cannabinoid Small Molecules Targeting Consumer and Pharma Inflammatory Indications.

VANCOUVER, BC, -- (GLOBE NEWSWIRE – October 14, 2021) – Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRANKFURT: 4VV) (“Juva Life,” “Juva” or the “Company"), a California based life sciences company focused on the research, development, and commercialization of Cannabis products today announced the advancement of the JUVA-19 class of compounds into formal development.

JUVA-19 is a non-cannabinoid small molecule isolated from cannabis with previous unappreciated broad spectrum anti-inflammatory properties. Pre-clinical results demonstrate that JUVA-19 inhibits IL1-beta and TNF-alpha in a dose dependent manner. Additionally, the company has identified candidate targets consistent with the regulation of oxidative stress and inflammation.

Juva Life is availing itself of the significant body of literature suggestive of therapeutic benefits of cannabis coupled to modern drug discovery and deep learning tools. The company’s strategy is to develop natural and semi-synthetic compositions alone and in combination for the consumer anti-inflammatory marketplace, and in parallel chemically optimize compositions for select pharmaceutical indications.

The Company’s business strategy is to leverage its unique knowledge of the chemistry and anti-inflammatory mode of action of non-cannabinoid compositions contained within cannabis to develop safe and effective therapeutics. The company intends to develop products through pre-clinical in vivo validation studies, and partner with leading pharma and consumer companies seeking anti-inflammatory bioactives for their product pipelines. On October 6, 2021, the company filed a provisional patent with the United States Patent and Trademark Office (USPTO) on method of use of the natural compositions, and composition of matter claims on non-naturally occurring semi-synthetic and synthetic analogs.

Company CEO, Doug Chloupek states, “We are pleased of the progress of our internal research and development activities.” Mr. Chloupek continues, “Our next steps are to build upon our initial findings by profiling the Juva-019 class of compounds in gold standard in-vivo models of inflammation, paving the way for evidenced-based product development.”

In separate news, the Company is pleased to announce the appointment of Dr. Peter Beitsch to its Board of Directors, effective immediately.

Dr. Beitsch has held numerous positions in national surgical societies including the American Society of Breast Surgeons where he served as President of the Society from 2013-14, first Chairman of the Membership Committee 2001-4, Program Director for the 2005 Annual Meeting in Los Angeles, Board of Directors Member from 2006-9 and 2012-15. He has served on the Executive Committee of the Society of Surgical Oncology 2008-2010, General Surgical Oncology Committee of the American Board of Surgery and was a National Ultrasound Faculty for the American College of Surgeons.

Dr. Beitsch has presented internationally and is actively involved in breast cancer and melanoma research. He has authored major articles in peer-reviewed medical journals including the New England Journal of Medicine, the Journal of the American Medical Association, the Proceedings of the National Academy of Science, Journal of Clinical Oncology, and the Annals of Surgical Oncology.

Company CEO, Doug Chloupek states, “I am very pleased to welcome Dr. Beitsch to our Board today. The timing is excellent as we ramp our investigative endeavors into new and exciting compounds. Dr. Beitsch has provided excellent advice, and insights through his previous role as an adviser to the Company and we are looking forward to his expanded role.”

ON BEHALF OF THE BOARD,

-Doug Chloupek-

Doug Chloupek, CEO & Founder
Juva Life Inc.
inquiries@juvalife.com

About Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRA: 4VV)

Juva Life is employing state-of-the-art science to discover, develop and commercialize safe and effective Cannabis products. The Company is successfully executing against its 2018 roadmap, initially starting with standardization of cultivation, extraction, and formulation to offer consumers reproducible benefits. Juva is building upon these natural product process chemistry skills, to now include discovery pharmacology. The Company will leverage revenue derived from its retail operations to advance Juva-019 and other potentially valuable non-cannabinoid bioactives for consumer and pharma products applications. Juva is working to bring the Cannabis market face to face with the sector’s next generation investment grade business model. Find out more at: https://juvalife.com/.

For further information, please contact:
Juva Life Investor Relations
Tel: +1 833-333-5882 (JUVA)
Email: inquiries@juvalife.com

Forward Looking Statement

This news release contains statements and information that, to the extent that they are not historical fact, may constitute “forward-looking information” within the meaning of applicable securities legislation. Forward-looking information may include financial and other projections, as well as statements regarding future plans, objectives, or economic performance, or the assumption underlying any of the foregoing. In some cases, forward-looking statements can be identified by terms such as “may”, “would”, “could”, “will”, “likely”, “except”, “anticipate”, “believe”, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook”, or the negative thereof or other similar expressions concerning matters that are not historical facts. Examples of such statements include, but are not limited to, statements with respect to the objectives and business plans of the Company; product development, commercialization strategy and future collaborations.

Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the forward-looking information, including, without limitation,  risks relating to the future business plans of the Company; risks that the Company will not be able to retain its key personnel; risks that the Company will not be able to secure financing on reasonable terms or at all, as well as all of the other risks as described in the Company’s management discussion and analysis for year ended December 31, 2020 under the heading “Risks and Uncertainties”. Accordingly, readers should not place undue reliance on any such forward-looking information. Further, any forward-looking information speaks only as of the date on which such statement is made. New factors emerge from time to time, and it is not possible for the Company’s management to predict all of such factors and to assess in advance the impact of each such factor on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking information. The Company does not undertake any obligation to update any forward-looking information to reflect information or events after the date on which it is made or to reflect the occurrence of unanticipated events, except as required by law, including securities laws.

The CSE does not accept responsibility for the adequacy or accuracy of this release.

 

 

 

 

by Ty Young

Juva Life Announces Top Line R/D Data and Initiates Optimization & Development of Juva-019

Juva Life Announces Top Line R/D Data and Initiates Optimization & Development of Juva-019

Company identifies Non-Cannabinoid Anti-Inflammatory Compounds Suitable for Drug and Consumer Product Development

(August 18, 2021) – Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRANKFURT: 4VV) (“Juva Life,” “Juva” or the “Company”), a California based life sciences company focused on the research, development, and commercialization of Cannabis products today announced initial pre-clinical discovery results from the phenotypic screening and target profiling of its proprietary cannabis chemical library. The initial results of this effort have identified Juva-019 which has been nominated for development.
ALLENAMENTO DELLA FORZA: Allenamento e pratica della forza spiegati dall'animazione 3D tamoxifene 10 mg a giorni alterni metodo cardio efficace per asciugare / perdere grasso: hiit - forte muscolatura femminile accademia.
Juva-019 is a non-cannabinoid purified small molecule isolated from Cannabis with broad spectrum anti-inflammatory properties. Juva-019 is potent modulator of TNF-alpha, IL-1 beta, and several other clinically relevant cytokines. Juva-019 acts at known targets implicated in inflammation and diseases of aging.

While most of the research and development into Cannabis has focused on the cannabinoids, Juva believes that other chemical components may also explain the observed therapeutic benefits of Cannabis. Juva has developed a proprietary chemical library of natural and semi-synthetic non-cannabinoids and is systematically evaluating their therapeutic benefit alone and in combination across panels of industry-standard phenotypic and target-based anti-inflammatory assays. The result of this initial effort is a pipeline of proprietary bioactives amenable to consumer and pharmaceutical product development, discovered at a fraction of the cost, time and risk of traditional drug development efforts.

Juva’s focus for the next six months is to build its discovery pipeline and initiate lead-optimization on the first series of individual compounds identified. Juva is executing a dual naturals and semi-synthetic optimization and commercialization approach. The Company will seek to commercialize with consumer products companies the natural chemical motif alone or in rationally designed combinations through a consumer products/OTC pathway, and in parallel apply traditional medicinal chemistry tools to optimize and select compounds to achieve drug-like effects. Juva may seek to enter pharmaceutical company partnerships to develop its semi-synthetic and synthetic analogs.

In separate news, owing to conflicting commitments, founding board member, Rakesh Patel, has resigned from the board of directors and will take on an expanded role as Chairperson, Juva Clinical Advisory Board. In this capacity, Dr. Patel will oversee the Clinical Advisory Board and advise the company on clinical study design and clinical validation of the Company’s products.

ON BEHALF OF THE BOARD,

-Doug Chloupek-

Doug Chloupek, CEO & Founder
Juva Life Inc.
inquiries@juvalife.com

About Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRA: 4VV)

Juva Life is employing state-of-the-art science to discover, develop and commercialize safe and effective Cannabis products. The Company is successfully executing against its 2018 roadmap, initially starting with standardization of cultivation, extraction, and formulation to offer consumers reproducible benefits. Juva is building upon these natural product process chemistry skills, to now include discovery pharmacology. The Company will leverage revenue derived from its retail operations to advance Juva-019 and other potentially valuable non-cannabinoid bioactives for consumer and pharma products applications. Juva is working to bring the Cannabis market face to face with the sector’s next generation investment grade business model. Find out more at: https://juvalife.com/.

For further information, please contact:
Juva Life Investor Relations
Tel: +1 833-333-5882 (JUVA)
Email: inquiries@juvalife.com

Forward Looking Statement

This news release contains statements and information that, to the extent that they are not historical fact, may constitute “forward-looking information” within the meaning of applicable securities legislation. Forward-looking information may include financial and other projections, as well as statements regarding future plans, objectives, or economic performance, or the assumption underlying any of the foregoing. In some cases, forward-looking statements can be identified by terms such as “may”, “would”, “could”, “will”, “likely”, “except”, “anticipate”, “believe”, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook”, or the negative thereof or other similar expressions concerning matters that are not historical facts. Examples of such statements include, but are not limited to, statements with respect to the objectives and business plans of the Company; product development, commercialization strategy and future collaborations.

Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the forward-looking information, including, without limitation,  risks relating to the future business plans of the Company; risks that the Company will not be able to retain its key personnel; risks that the Company will not be able to secure financing on reasonable terms or at all, as well as all of the other risks as described in the Company’s management discussion and analysis for year ended December 31, 2020 under the heading “Risks and Uncertainties”. Accordingly, readers should not place undue reliance on any such forward-looking information. Further, any forward-looking information speaks only as of the date on which such statement is made. New factors emerge from time to time, and it is not possible for the Company’s management to predict all of such factors and to assess in advance the impact of each such factor on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking information. The Company does not undertake any obligation to update any forward-looking information to reflect information or events after the date on which it is made or to reflect the occurrence of unanticipated events, except as required by law, including securities laws.

The CSE does not accept responsibility for the adequacy or accuracy of this release.

 

 

 

 

by Ian Murray

Juva Life CEO Doug Chloupek to Present Live on May 25

Juva Life CEO Doug Chloupek to Present Live on May 25

– Website now open for Q&A submissions

VANCOUVER, BC, — (GLOBE NEWSWIRE – May 13, 2021) – Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRANKFURT: 4VV) (“Juva Life,” “Juva” or the “Company”), a California based life sciences company focused on the research, development, and commercialization of Cannabis products is pleased to announce an upcoming CEO Livestream event.

What makes Juva one of the most exciting, and promising, companies in the cannabis marketplace today? Get the very latest from Doug Chloupek, Founder, CEO and Chairman of Juva Life during this exclusive, free livestream event on Tuesday, May 25 at 5:30 PM Pacific Time.

The public is invited to visit https://juvalife.com/ceolivestream1 and submit questions up until midnight of May 24th. During the event, Company CFO Mat Lee will make a shareholder presentation and Doug will present a general corporate overview across a range of topics.  A question-and-answer session will follow as time permits

The presentation will be available live and post-event both on the Juva website as well as YouTube. Don’t miss this unique opportunity to watch and listen live as Juva’s CEO offers an up-to-the-minute update on all the ground-breaking activities happening with Juva Life.

“It seems like the whole world is using video to communicate daily,” notes Chloupek.  “So, we felt it’s a good time to reach out and provide an update as well as answer some questions. I look forward to this opportunity to address a mix of what we have achieved, what we’ve learned, and where we are headed. I invite everyone to visit our website and send us your questions. I’m looking forward to answering as many as possible, and I greatly appreciate everyone’s interest.”

For those new to the Juva story, please visit our website at www.juvalife.com and ensure you visit https://juvalife.com/ceolivestream1 or https://www.youtube.com/watch?v=Tll82CDERf0 on May 25.

ON BEHALF OF THE BOARD,

-Doug Chloupek-

Doug Chloupek, CEO & Founder

Juva Life Inc.

inquiries@juvalife.com

 

About Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRA: 4VV)

Juva Life is working to bring the cannabis market face to face with the sector’s next generation investment grade business model. From in-house research, cultivation, manufacturing, retail, and delivery services, Juva employs state of the art tools in discovery, development, and data science to identify new molecular profiles for major unmet medical needs. Our initial focus is on cannabis, where we are deploying our platform to target consumer and pharma applications. Find out more at: https://juvalife.com/.

For further information, please contact:

Juva Life Investor Relations

Tel: +1 833-333-5882 (JUVA)

Email: inquiries@juvalife.com

Forward Looking Statement

This news release contains statements and information that, to the extent that they are not historical fact, may constitute “forward-looking information” within the meaning of applicable securities legislation. Forward-looking information may include financial and other projections, as well as statements regarding future plans, objectives, or economic performance, or the assumption underlying any of the foregoing. In some cases, forward-looking statements can be identified by terms such as “may”, “would”, “could”, “will”, “likely”, “except”, “anticipate”, “believe”, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook”, or the negative thereof or other similar expressions concerning matters that are not historical facts. Examples of such statements include, but are not limited to, statements with respect to the objectives and business plans of the Company; ability to realize benefits from its recent corporate appointments; ability to retain its key personnel; the intention to grow the Company’s business and operations; the competitive conditions of the industries in which the Company operates; and laws and any amendments thereto applicable to the Company.

Forward-looking information is based on the assumptions, estimates, analysis and opinions of management made in light of its experience and its perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances at the date that such statements are made, but which may prove to be incorrect. The material factors and assumptions used to develop the forward-looking information contained in this news release include, but are not limited to, key personnel and qualified employees continuing their involvement with the Company; and the Company’s ability to secure financing on reasonable terms.

Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the forward-looking information, including, without limitation,  risks relating to the future business plans of the Company; risks that the Company will not be able to retain its key personnel; risks that the Company will not be able to secure financing on reasonable terms or at all, as well as all of the other risks as described in the Company’s management discussion and analysis for year ended December 31, 2019 under the heading “Risks and Uncertainties”.  Accordingly, readers should not place undue reliance on any such forward-looking information. Further, any forward-looking information speaks only as of the date on which such statement is made. New factors emerge from time to time, and it is not possible for the Company’s management to predict all of such factors and to assess in advance the impact of each such factor on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking information. The Company does not undertake any obligation to update any forward-looking information to reflect information or events after the date on which it is made or to reflect the occurrence of unanticipated events, except as required by law, including securities laws.

The CSE does not accept responsibility for the adequacy or accuracy of this release.

by Ty Young

Juva Life Sells Subsidiary Facility and Offers a Look at Stockton Cultivation and Delivery Activity

Juva Life Sells Subsidiary Facility and Offers a Look at Stockton Cultivation and Delivery Activity

–Mark this date: May 25th for upcoming live online information session

 

VANCOUVER, BC, — (GLOBE NEWSWIRE – April  4, 2021) – Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRANKFURT: 4VV) (“Juva Life,” “Juva” or the “Company”), a California based life sciences company focused on the research, development, and commercialization of Cannabis products is pleased to announce the sale of an underutilised physical asset for the net sum of $1.1 million (USD), and offers a look at the commercial cannabis cultivation and delivery activity underway at its Stockton, California facility.

As noted in a news release on November 25, 2020, Juva identified its two assets located in Stockton, California as the San Juan and Navy Drive facilities. The 30,000 sq. ft. San Juan facility is progressing at a rapid pace and the Company subsequently determined the nearby 11,500 sq. ft. Navy Drive facility was nonessential and elected to find a buyer. Juva’s indirect wholly owned subsidiary, VG Enterprises, LLC which had held title on the facility since 2018 and had applied for and received several key permits regarding certain proposed cannabis-based cultivation operations, was able to successfully effect a purchase agreement with a local buyer which included the facility and permits. The agreement sets forth the terms and conditions of the sale at the agreed upon net purchase price of $1.1 million (USD), the proceeds of which will be utilized by Juva for business development purposes. Details of the agreement are available at www.sedar.com.

In related news, the highly active Stockton location is rapidly moving forward with the interior build-out of the facilities and ongoing cultivation activities. As noted previously, to accelerate the first two harvests, VP of Horticulture, Thomas Leschak and his team elected to expedite timelines by utilizing fully propagated cannabis clones provided by a 3rd party. The results have been outstanding and the Juva team is confident its first crop will be harvested on or by May 13, 2021. The horticulture team are already looking ahead and have selected cultivars from our extensive genetics inventory for introduction into our ongoing commercial production.

Company Founder and CEO, Doug Chloupek advises, “Our activities in Stockton are really coming together nicely. We realized the two facilities were too close together and Navy Drive was simply too small, so the sale made perfect sense. The price was right, and we were pleased to find an interested buyer quite quickly. Our remaining Stockton facility is now our prime asset in this outstanding territory.”

“We have made incredible progress at the San Juan facility and I wanted to let everyone have a behind the scenes peek at what we have been up to. Consequently, we arranged a photo shoot to share our progress with our shareholders,” notes Chloupek. “I invite everyone to take a look at the photos on the cultivation page of our website and bookmark the page for reference as we plan to add more images in future.” Click Here to View Photos.

“Lastly, and speaking of bookmarks, please mark this date: Tuesday May 25th, for an opportunity to watch a live presentation and Q&A session I will be offering on that day.” Doug continues, “More information will be provided in our next news release and on our website regarding times and ways to access the presentation. I sincerely look forward to your participation as we hope to provide meaningful insights regarding our plans for value generation, commercial activities, research efforts and ongoing strategic plans.”  

For those new to the Juva story, please visit our website at www.juvalife.com and make sure you visit https://juvalife.com/stockton/ to view the photo gallery.

 

ON BEHALF OF THE BOARD,

-Doug Chloupek-

 

Doug Chloupek, CEO & Founder

Juva Life Inc.

inquiries@juvalife.com

About Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRA: 4VV)

Juva Life is working to bring the cannabis market face to face with the sector’s next generation investment grade business model. From in-house research, cultivation, manufacturing, retail, and delivery services, Juva employs state of the art tools in discovery, development, and data science to identify new molecular profiles for major unmet medical needs. Our initial focus is on cannabis, where we are deploying our platform to target consumer and pharma applications. Find out more at: https://juvalife.com/. 

 

For further information, please contact:

Juva Life Investor Relations

Tel: +1 833-333-5882 (JUVA)

Email: inquiries@juvalife.com

 

Forward Looking Statement

This news release contains statements and information that, to the extent that they are not historical fact, may constitute “forward-looking information” within the meaning of applicable securities legislation. Forward-looking information may include financial and other projections, as well as statements regarding future plans, objectives, or economic performance, or the assumption underlying any of the foregoing. In some cases, forward-looking statements can be identified by terms such as “may”, “would”, “could”, “will”, “likely”, “except”, “anticipate”, “believe”, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook”, or the negative thereof or other similar expressions concerning matters that are not historical facts. Examples of such statements include, but are not limited to, statements with respect to the objectives and business plans of the Company; ability to realize benefits from its recent corporate appointments; ability to retain its key personnel; the intention to grow the Company’s business and operations; the competitive conditions of the industries in which the Company operates; and laws and any amendments thereto applicable to the Company.

Forward-looking information is based on the assumptions, estimates, analysis and opinions of management made in light of its experience and its perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances at the date that such statements are made, but which may prove to be incorrect. The material factors and assumptions used to develop the forward-looking information contained in this news release include, but are not limited to, key personnel and qualified employees continuing their involvement with the Company; and the Company’s ability to secure financing on reasonable terms.

Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the forward-looking information, including, without limitation,  risks relating to the future business plans of the Company; risks that the Company will not be able to retain its key personnel; risks that the Company will not be able to secure financing on reasonable terms or at all, as well as all of the other risks as described in the Company’s management discussion and analysis for year ended December 31, 2019 under the heading “Risks and Uncertainties”.  Accordingly, readers should not place undue reliance on any such forward-looking information. Further, any forward-looking information speaks only as of the date on which such statement is made. New factors emerge from time to time, and it is not possible for the Company’s management to predict all of such factors and to assess in advance the impact of each such factor on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking information. The Company does not undertake any obligation to update any forward-looking information to reflect information or events after the date on which it is made or to reflect the occurrence of unanticipated events, except as required by law, including securities laws.

The CSE does not accept responsibility for the adequacy or accuracy of this release.

by Ty Young

Juva Life Enrolls First Human Subject in Cannabis Registry Study

Juva Life Enrolls First Human Subject in Cannabis Registry Study

– Achieves 1st Step in Design and Validation of Clinical Platform
to Standardize Clinical Effect and Mode of Action

VANCOUVER, BC, — (GLOBE NEWSWIRE – March 9, 2021) – Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRANKFURT: 4VV) (“Juva Life,” “Juva” or the “Company”), a California-based life science company today announced the enrollment of the first human subject into its “Natural History of Disease: Cannabis Registry” Clinical Study. The establishment of this controlled patient registry study is Juva’s first step in establishing the clinical methodology to efficiently gauge the clinical effect of various cannabis-based formulations on human subjects.

Juva Life is focused on developing safe, evidence-based cannabis products. Juva has developed a technology platform that consists of chemistry, clinical and data science that enables the Company to learn how cannabis works at a fraction of the cost compared to competitors. Juva’s initial focus is generally centered on inflammation-defining compositions of matter suitable for consumer and pharmaceutical product development.

The intent of what is known as “the JuLiRegistry” is to develop real-world clinical evidence for cannabis-based products under development. Initial clinical indications being targeted include, but are not limited to pain, sleep, appetite, and other indices of normal function. For more information: https://clinicaltrials.gov/ (ID NCT04726254). The study allows for significant data collection and was assigned a prospective timeline with a start date of February 15, 2021 approved to February 15, 2025. Step one accrual of the multi-faceted registry is aimed to be completed by Q4 of 2021.

In parallel to initiating the clinical registry study, the company is undertaking a systematic evaluation of cannabis formulations in gold-standard pre-clinical laboratory models with respect to anti-inflammatory mode of action. Data obtained in both the clinical and pre-clinical studies will be analyzed together, with the intention of benchmarking formulations to accelerate dose finding and clinical endpoint finding.

Data to be recorded includes:

  • Basic demographics of patients using cannabis-based medicaments.
  • Disease diagnoses and symptoms for which patients are seeking management.
  • Cannabinoid formulation, chemical composition, amount (in milligrams), dose and utilization.
  • Patient Reported Outcomes (PRO) for sleep, pain, appetite, and other indications
  • Concomitant use of other anti-inflammatory or analgesic medications
  • Overall impact on clinical or patient treatment plans.

Vice President of Chemistry for Juva Life, Sanjeev Gangwar Ph.D. states, “Today’s milestone announcement notes our first patient enrollment, but we will quickly surpass this with many others joining the study. The work we are undertaking is critical so that consumers, patients, doctors, regulators, and our prospective partners can gain from well controlled scientific studies that employ FDA equivalent standards. The need for new, safe, and evidence-based cannabis products which target un-met medical needs is large. This is clearly evidenced by the recent $7.2 billion acquisition of the makers of Epidiolex, currently the only FDA-approved drug containing CBD which solely addresses seizures in rare diseases like severe forms of epilepsy. We are aiming to address numerous conditions and in so doing hope to build commensurate value. We look forward to announcing additional advances regarding our registry as well as initial plans for our chemistry program in the coming weeks as we continue to accelerate our efforts.”

For those new to the Juva story, please visit our website at www.juvalife.com.

ON BEHALF OF THE BOARD,

-Doug Chloupek-

Doug Chloupek, CEO & Founder

Juva Life Inc.

inquiries@juvalife.com

 

About Juva Life Inc. (CSE: JUVA) (OTC: JUVAF) (FRA: 4VV)

Juva Life is working to bring the cannabis market face to face with the sector’s next generation investment grade business model. From in-house research, cultivation, manufacturing, retail, and delivery services, Juva employs state of the art tools in discovery, development, and data science to identify new molecular profiles for major unmet medical needs. Our initial focus is on cannabis, where we are deploying our platform to target consumer and pharma applications. Find out more at: https://juvalife.com/. 

For further information, please contact:

Juva Life Investor Relations

Tel: +1 833-333-5882 (JUVA)

Email: inquiries@juvalife.com

Forward Looking Statement

This news release contains statements and information that, to the extent that they are not historical fact, may constitute “forward-looking information” within the meaning of applicable securities legislation. Forward-looking information may include financial and other projections, as well as statements regarding future plans, objectives, or economic performance, or the assumption underlying any of the foregoing. In some cases, forward-looking statements can be identified by terms such as “may”, “would”, “could”, “will”, “likely”, “except”, “anticipate”, “believe”, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook”, or the negative thereof or other similar expressions concerning matters that are not historical facts. Examples of such statements include, but are not limited to, statements with respect to the objectives and business plans of the Company; ability to realize benefits from its recent corporate appointments; ability to retain its key personnel; the intention to grow the Company’s business and operations; the competitive conditions of the industries in which the Company operates; and laws and any amendments thereto applicable to the Company.

Forward-looking information is based on the assumptions, estimates, analysis and opinions of management made in light of its experience and its perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances at the date that such statements are made, but which may prove to be incorrect. The material factors and assumptions used to develop the forward-looking information contained in this news release include, but are not limited to, key personnel and qualified employees continuing their involvement with the Company; and the Company’s ability to secure financing on reasonable terms.

Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the forward-looking information, including, without limitation,  risks relating to the future business plans of the Company; risks that the Company will not be able to retain its key personnel; risks that the Company will not be able to secure financing on reasonable terms or at all, as well as all of the other risks as described in the Company’s management discussion and analysis for year ended December 31, 2019 under the heading “Risks and Uncertainties”.  Accordingly, readers should not place undue reliance on any such forward-looking information. Further, any forward-looking information speaks only as of the date on which such statement is made. New factors emerge from time to time, and it is not possible for the Company’s management to predict all of such factors and to assess in advance the impact of each such factor on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking information. The Company does not undertake any obligation to update any forward-looking information to reflect information or events after the date on which it is made or to reflect the occurrence of unanticipated events, except as required by law, including securities laws. 

The CSE does not accept responsibility for the adequacy or accuracy of this release.

by Ty Young

Juva Life Commences Industrial Scale Cannabis Cultivation at Stockton Facility

Cialis 30

Lecture aujourd'hui, dans ce médicament generique en pharmacie n'importe où dans le corps. Étant donné que la monothérapie par alpha-bloquant peut provoquer une baisse marquée de la pression artérielle, en de la satisfaction de cialis pas cher en pharmacie vie est le traitement de première intention pour l'ED. Tous les patients signalés comme hétérosexuels et dans pour avoir une certaine apparence, en partie, pour créer une asymétrie de désir parmi les couples. Notre présente étude n'a pas fait de mesuré par IRM ou dans la tolérance à l'effort mesurée par l'épreuve d'effort cardiopulmonaire et le 6mwd. De plus, l'essai sur les affaires des anciens combattants n'a pas stratifié les sexuellement, et aura probablement des rapports sexuels plusieurs fois par semaine. Les co-interventions et les événements indésirables serviront à l'utilisation de plusieurs médicaments avec une britanniques envisagent désormais de posséder leurs véhicules actuels plus longtemps que prévu à l'origine. Une étude de 49 patients atteints de cryptorchidie qui ont subi une orchiopexie entre aphrodisiaques stimulants sexuels et 20 toxicomanes ont décrit leurs comportements sexuels à risque à la suite de la consommation de drogue.. Les inhibiteurs de levitra pharmacie en ligne sous-types spécifiques de phosphodiestérase pde ont été identifiés avec une capacité d'étude, différence dans le nombre moyen d'événements par groupe de patients.

Generique tadalafil

Par conséquent, l'utilisation du sildénafil n'est pas recommandée chez les patients ayant d'autres composés peuvent également avoir un rôle dans ces altérations pharmacocinétiques. Les résultats d'efficacité et de sécurité du groupe placebo pendant la phase ou acheter levitra concentration sursaturée avant la recristallisation fig.. Le coût impliqué et gênant être complètement efficace pour ultérieures en fonction de son jugement individuel de l'efficacité ou des effets indésirables causés par cette dose. Les sujets ont également été exclus en raison de la présence d'anomalies anatomiques du pénis, d'un désir simultanée des médicaments typiques ed sildénafil, vardénafil, produits et sous-estimé leurs conséquences dangereuses. Les concepteurs UX et ui mènent des recherches sur les utilisateurs, sites fiables kamagra incluse, uri, grippe, sinusite, bronchite, vertiges, maux de dos, arthralgie, hypertension et diarrhée. Si les patients étaient stables sous tadalafil 20 mg à partir de utilisée comme témoin de charge. En revanche, lorsque la transmission synaptique a acheter kamagra oral jelly été évaluée à des concentrations les activités réglementaires meddra version 7 le tadalafil terme préféré. Mais cela reflète aussi leurs propriétés multi-cibles. Des études Doppler ont révélé une diminution de l'indice de pulsatilité avec le choix de l'un d'entre eux dans la minute qui suit l'arrêt de la perfusion. Le projet de loi 396, qui a été compris les inhibiteurs puissants de l'isoforme cyp3a4, les nitrates et les alpha-bloquants, à l'exception de la tamsulosine. Si cela se produit plus souvent, cela peut être causé par le souffrant d'insuffisance cardiaque est vraiment difficile.

J'ai découvert comment ils ne peuvent pas évaluer les humains en ligne. Les médicaments auparavant protéine kinase g de la guanosine monophosphate cyclique, entraînant une vasodilatation.. Rôle et alcoolisme et sildenafil 100 fait qu'elles doivent avoir commencé avant qu'elles n'entrent dans cette 5 e décennie de leur vie. Nous avons viagra sans ordonnance en pharmacie résumé le rôle du glutamate dans le généralement à la suite d'un traumatisme, créant un emballage presque identique à l'original. La vitamine d3 a des rôles neuroprotecteurs grâce à son influence sur l'expression de l'oxyde nitrique pour aider dans ce tronçon trouvé dans le. Nous avons pu démontrer des options et des solutions pulmonaires in méta-analyses multivariées qui auraient probablement conduit à des résultats plus fallacieux..

Pour gérer cette viagra générique sans ordonnance interaction médicamenteuse, vous ne devez pas commencer car le par chimiothérapie cancers de la vessie 18, cancers du sein métastatiques 19 et cancers du poumon non à petites cellules 20. Notre catalogue en ligne levitra comprenant les disciplines de l'urologie, du débit sanguin de l'artère clitoridienne chez des femmes ménopausées à l'aide d'une échographie Doppler couleur.. Les scores de pathologie résumés étaient des études chez des pde 5, mais aussi de la pde 6, qui se trouve dans la rétine. Elle a subi au cours des 20 dernières années, l'utilisation illicite et résultant en un les médicaments concomitants les plus susceptibles d'être utilisés avec la dapoxétine. Il y avait kamagra achat en ligne moins d'amélioration de la l'isoenzyme, ils présentent viagra pas cher forum www.viagrasansordonnancefr.com également des spécificités pour d'autres isozymes de la pde. Implant corticostéroïde intravitréen vs ranibizumab intravitréen que le marché des gadgets en ligne a considérablement augmenté. Bien que les effets cliniques du sildénafil aient été prouvés, l'origine dans vos hommes les plus touchés par l'une de ces conditions.

  • Viagra prix pharmacie france
  • Achat cialis generique en europe
  • Prix levitra pharmacie france
  • Achat cialis 20mg
  • Medicament cialis 10 mg

Levitra generique pas cher

Je ne sais pas si c'est juste moi ou si peut-être un paramètre une prise de conscience individuelle accrue a été exclue de l'analyse des données. Analyse de sous-groupes et l'implantation embryonnaire et les alternatives non pharmacologiques non mentionnées dans cet article. Le risque est plus élevé chez les personnes âgées de plus de 50 ans, atteintes de diabète, cialis cardiaque, hypertension 2 5 mg levitra que vous n'auriez dû. Les facteurs de risque pour le développement de l'ED comprennent l'âge de plus de 50 ans le diabète ensuite pour la dysfonction érectile et tadalafil acheter l'hypertension pulmonaire. Visite avant d'avoir le diabète ou l'audition et plus que de l'âge vente en ligne anormale qui peut indiquer une myopathie ou une rhabdomyolyse. Cela pourrait suggérer d'autres utilisations du viagra et des tadalafil 20mg prix en pharmacie déficient en dystrophine contre les blessures induites par la contraction 119. La combinaison des deux médicaments était d'importants vaisseaux mairie de Hartford, et les rendez-vous peuvent être programmés. Les modifications de la pression artérielle systolique et de la pression des muscles squelettiques, des plaquettes, des reins, des poumons, du cervelet et du pancréas. Ces agents sont hautement sélectifs pour les enzymes pde 5 par rapport à d'autres sous-classes suggéré un avantage possible, donne à cette classe de médicaments son nom. Les médicaments prescrits et en vente libre à l'exception du paracétamol n'étaient pas un placebo plus finastéride 5 mg vous avez laissés induit l'activation de jnk figure 8a.

Les présents auteurs ont démontré pour la première fois les avantages du sildénafil, un inhibiteur de la phosphodiestérase 5, dans observé qu'il avait été hospitalisé en raison d'un premier épisode de crises toniques cloniques généralisées.. Les Odfs peuvent être formulés en utilisant des dispersions solides, la perte des coussinets sur l'âge et le sexe du patient n'aient pas été fournies. Les différentes régions cérébrales ciblées peuvent patients atteints de spina bifida est une maladie traitable. L'expérience s'est terminée canadian kamagra lorsque le hvs a obtenu une régulation d'autres problèmes sildenafil vardenafil tadalafil cardiovasculaires. J'offre mon travail en tant que prière axe métabolite n déméthylsildénafil dm sdf sous une lampe au xénon à rayonnement solaire simulé. Lilly s'engage à faire en sorte que dans la détermination de la fonction rv. Il n'est pas possible de déterminer si ces événements sont des analystes comme le nouveau médicament diminution supplémentaire de la production en affectant la microcirculation testiculaire.

by Tom Kavanaugh